Kantonsspital Winterthur

Running trials

• Recruiting

  Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT07149649· Phase 2/3· Source

• Recruiting

  Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC

  NCT07158489· Phase 2· Source

• Recruiting

  Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro)

  NCT07365423· Phase 2· Source

• Recruiting

  LUCINAE Registry: Thoracic Cancers During Pregnancy

  NCT07699861· Source

• Recruiting

  Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

  NCT07020065· Phase 2· Source

• Recruiting

  A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy

  NCT06931717· Phase 3· Source

• Recruiting

  Improving Functional Outcomes and Quality of Life in Patients With Rectal Cancer After Surgery With Intensified Follow-up & Surveillance

  NCT06936774· Phase 3· Source

• Recruiting

  Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE)

  NCT06835049· Phase 2· Source

• Recruiting

  Fiber-Boost Randomized Controlled Trial

  NCT07483112· Source

• Recruiting

  Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer

  NCT07617610· Source

• Recruiting

  Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer

  NCT05815927· Phase 3· Source

• Recruiting

  OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy

  NCT06466382· Source

• Recruiting

  Personalized Volume-deescalated Elective Nodal Irradiation in Oropharyngeal Head and Neck Squamous Cell Carcinoma

  NCT06563362· Phase 2· Source

• Recruiting

  A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

  NCT06284317· Phase 3· Source

• Active, not recruiting

  Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  NCT06760637· Phase 3· Source

• Recruiting

  Hyperoxia During Outpatient Pulmonary Rehabilitation in Chronic Lung Disease - Does it Matter?

  NCT06776731· Source

• Recruiting

  Skin Cancer and Hyperthermia and Radiotherapy

  NCT06384053· Source

• Recruiting

  Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

  NCT06358573· Phase 2· Source

• Recruiting

  Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  NCT06401980· Phase 2· Source

• Recruiting

  Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

  NCT06598306· Phase 1· Source

• Recruiting

  Association of Ultrasound Features of the Myometrium Suggestive of Adenomyosis and Clinical Symptoms

  NCT07397715· Source

• Recruiting

  A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  NCT06119581· Phase 3· Source

• Recruiting

  Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC

  NCT05718323· Phase 2· Source

• Active, not recruiting

  Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

  NCT05740566· Phase 3· Source

• Recruiting

  Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer

  NCT05522660· Phase 3· Source

• Recruiting

  A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

  NCT05623020· Phase 3· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  NCT05382286· Phase 3· Source

• Active, not recruiting

  Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

  NCT05317416· Phase 3· Source

• Active, not recruiting

  A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

  NCT05132582· Phase 3· Source

• Active, not recruiting

  Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.

  NCT04604067· Phase 2· Source

• Active, not recruiting

  Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).

  NCT04472949· Phase 2· Source

• Active, not recruiting

  A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

  NCT04680052· Phase 3· Source

• Active, not recruiting

  Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

  NCT04608318· Phase 3· Source

• Recruiting

  MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)

  NCT04111978· Phase 3· Source

• Recruiting

  Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)

  NCT05017142· Source

• Active, not recruiting

  Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC

  NCT03965468· Phase 2· Source

• Recruiting

  Swiss Sarcoma Network: Prediction Model for Patient Selection in Sarcoma Care

  NCT04300257· Source

• Recruiting

  CARDSUP - SWISS Circulatory Support Registry

  NCT04117230· Source

• Recruiting

  Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress

  NCT03968393· Phase 4· Source

• Active, not recruiting

  Enhancement of Stroke Rehabilitation With Levodopa

  NCT03735901· Phase 3· Source

• Recruiting

  The SwissPrEPared Study

  NCT03893188· Source

• Active, not recruiting

  1st Line Durvalumab in PS 2 NSCLC Patients

  NCT03620669· Phase 2· Source

• Active, not recruiting

  Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer

  NCT03540420· Phase 2· Source

• Recruiting

  Swiss Primary Biliary Cholangitis Cohort Study

  NCT03146910· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer11 recruiting
• Colorectal cancer2 recruiting
• Head and neck cancer2 recruiting
• Melanoma2 recruiting
• Ovarian cancer2 recruiting
• Prostate cancer2 recruiting
• Sarcoma2 recruiting
• Atrial fibrillation1 recruiting
• Childhood cancers1 recruiting
• COPD1 recruiting
• Endometriosis1 recruiting
• HIV1 recruiting
• Multiple myeloma1 recruiting
• Multiple sclerosis1 recruiting
• Neuromyelitis optica (NMOSD)1 recruiting
• Primary biliary cholangitis1 recruiting
• Stroke1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Withdrawn

  AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC

  NCT06068153· Phase 2· Source

• Completed

  Influencing Factors for Physical Activity in People With Head and Neck Cancer

  NCT06272513· Source

• Completed

  Hyperoxia During Pulmonary Rehabilitation in Chronic Lung Disease - Does it Matter?

  NCT06174207· Source

• Completed

  Influence of a Home-based Nutrition and Exercise Program on Quality of Life of Palliative Cancer Outpatients

  NCT04859400· Source

• Terminated

  A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

  NCT04832854· Phase 2· Source

• Completed

  SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II

  NCT04480372· Phase 2· Source

• Completed

  Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

  NCT04303780· Phase 3· Source

• Completed

  BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

  NCT03762018· Phase 3· Source

• Terminated

  Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL

  NCT03708003· Phase 2· Source

• Completed

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· Phase 3· Source

• Completed

  Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

  NCT03353831· Phase 3· Source

• Completed

  Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma

  NCT03297593· Phase 2· Source

• Completed

  Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M

  NCT03133546· Phase 2· Source

• Completed

  Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)

  NCT02572843· Phase 2· Source

• Terminated

  Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

  NCT02051218· Phase 3· Source

• Terminated

  SwissNET - a Registry for Neuroendocrine Tumours in Switzerland

  NCT01039922· Source